Revolution Medicines jobs

Senior Medical Director - Late Phase Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking an experienced clinical science drug developer to serve as Senior Medical Director in support of Revolution Medicines' clinical-stage molecule(s). In this critical role, you will support various clinical science deliverables and enable effective and efficient execution of the clinical development plan for a molecule(s) within its particular indication(s). The physician-scientist will focus on ensuring the accuracy, completeness, and integrity of clinical data supporting regulatory submissions (NDA, BLA, MAA). This role is uniquely positioned at the interface of clinical development, regulatory science, clinical data, and clinical operations, and will be instrumental in preparing pivotal datasets from the pivotal and supportive studies for successful global filings. The ideal candidate brings a strong foundation in clinical medicine (M.D. or equivalent), oncology experience, and proven expertise in clinical trial data review, cleaning, and regulatory submission preparation. The scope of data review and

Associate Director, Tax Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Revolution Medicines is seeking a motivated individual with a tax background to play a critical role as a Associate Director of Tax within the finance department. Partnering with the Senior Director of Tax and finance team, the Associate Director will support global tax strategy, provision, and compliance, acting as a key cross-functional collaborative partner with R&D, international, and commercial teams to achieve business goals and meet the financial obligations of the organization. The role is an individual contributor reporting to the Senior Director of Tax and will work closely with external tax advisors, auditors, and internal stakeholders. Current tax department of two, with the possibility of expanding the team as the company advances. Responsibilities include: - Assist in the management and development of Company's international, US and state tax strategy. - Assist with and/or drive the research of complex tax technical topics, ultimately positioning

Senior Manager, Marketing, Lung Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: As a Senior Marketing Manager, you will be a key contributor to the development of compelling omnichannel campaigns that promote Revolution Medicine's values, scientific innovation, and patient centricity. You will develop and execute marketing strategies and plans to achieve brand objectives and growth targets, particularly for non-personal promotion initiatives. Identification and implementation of innovative digital promotion technologies will be essential to this role. You will also collaborate cross-functionally and support media planning, campaign measurement, campaign asset promotional review, and related expense budgets. - Engages in strategic market planning through developing and executing marketing strategies for lung cancer products and indications. - Understands customer needs and preferences to create engaging and effective marketing campaigns. - Oversees the execution of marketing campaigns across various channels, including digital, print, and field-based resources. - Tracks and analyzes marketing campaign performance to identify areas for improvement and provide recommendations for

Senior Manager, Global Patient Safety Operations Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: This position will be responsible for the management, development, and oversight of Global Patient Safety operational activities in the execution of safety information collection and reporting for the assigned Revolution Medicines' clinical programs. - Participates in the development of Global Patient Safety Operations operational objectives, policies, and procedures. - Represent Global Patient Safety in different cross functional team meetings. - Collaborate with other functional groups to achieve clinical program goals. - Oversee Pharmacovigilance Contract Research Organization (PV CRO) in the execution of safety reporting in clinical studies. - Manage PV CROs to ensure compliance with required timelines, that potential issues are being communicated, and resolution is achieved in a timely manner. - Oversee reporting of safety reports to global regulatory authorities, central IRB/ethics committees, investigators to ensure compliance with global regulatory requirements. - Ensure timely and accurate set up of global

Scientist I, Quantitative Systems Pharmacologist Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a QSP modeling & simulation scientist to be part of the Nonclinical Development and Clinical Pharmacology (NDCP) organization. This position will be responsible for developing, validating, and executing modeling projects with a focus on mechanistic PBPK-QSP mathematical models for small molecule programs to increase mechanistic understanding of compound PK behavior and drug distribution, pharmacological effects on RAS targets, support clinical translation, and drive future discovery and development efforts. As a Quantitative Systems Pharmacologist, you will: - Develop, validate, execute, and refine quantitative systems pharmacology (QSP) models, minimal physiologically based pharmacokinetic (PBPK) models, semi-mechanistic PK/PD models, and tumor growth models to support development and discovery phase projects including next-generation inhibitor design and assessment of combination potential. - Propose and perform in silico simulations to answer complex mechanistic questions, create data visualizations to effectively communicate modeling results to a wide-ranging audience,

Associate Director, Learning & Engagement Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: This is an exciting opportunity to lead the Learning & Engagement initiatives. The Associate Director, Learning & Engagement will lead the design, development and implementation of learning initiatives, instructional design solutions, learning forums, and infrastructure initiatives across partnered functions and in close alignment with HR and RevMed Learning and Engagement functions' best practices. This role requires a blend of Learning & Development expertise, a solid understanding of drug development processes & skillsets, and the communication abilities to support a diverse portfolio of strategic growth initiatives. Responsibilities: - Lead and deliver innovative learning programs that support the implementation and continuous improvement of DCS Growth & Enablement strategic roadmap and initiatives. - Drive the adoption of new business processes through training, communication, knowledge management, and change management. - Collaborate within Business Operations and across department leaders and functional subject-matter experts to assess training needs,

Vice President Sales and Field Team - NSCLC Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Vice President, Oncology Sales will lead the design, build, and execution of a high-performing, national oncology sales organization supporting Revolution Medicines products/services to the oncology communityg. Reporting to the SVP of US Marketing & Sales, the VP will be responsible for creating and scaling a best-in-class sales organization, ensuring successful product launches, and driving sustained revenue growth. This leader will combine strategic vision with operational rigor, leveraging deep oncology expertise and cross-functional collaboration to position the organization for long-term success. Key Responsibilities: Organizational Build & Leadership - Architect and execute the build-out of a national oncology sales organization, including hiring, onboarding, and development of regional leaders, account directors, and sales representatives. - This will include nurse educator and other field facing roles or functions including sales operations and training. - Establish organizational structure, roles, and deployment strategy aligned to brand

Associate Director, Accounting - Japan Remote (Japan) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Revolution Medicines is seeking an experienced, strategic, and hands-on accounting leader to build and scale the accounting and finance operations infrastructure in Japan. Reporting directly to the Head of Finance & Operations, Japan, this newly created role will play a critical role in supporting the company's transition toward future commercial readiness and long-term growth in Japan. This position will lead core accounting operations, financial systems implementation, process design, internal controls, and statutory compliance, while partnering cross-functionally to establish a scalable and compliant finance environment capable of supporting a commercial-stage organization. The role will also serve as a key business partner across Finance, Commercial, Legal, Supply Chain, HR, and global teams to help prepare the organization for future product launches and increasing operational complexity. The ideal candidate combines strong technical accounting expertise with operational leadership, systems implementation experience, and the ability to build processes and infrastructure

Principal Product Manager, Clinical Trials Intelligence Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a Principal Product Manager, Clinical Trials Intelligence to build products that help teams plan, run, monitor, analyze, submit, and follow clinical trials with greater speed, quality, and confidence.This role will define and deliver product strategy across the clinical trial continuum, from study design and startup through trial conduct, submission readiness, and post-approval safety monitoring. You will shape Clinical Trials Intelligence capabilities on RevCore, our enterprise data and AI platform, with a clear mandate to improve trial execution, enrollment predictability, data readiness, submission readiness, inspection readiness, and safety monitoring. You will work on high-stakes products where trust, usability, traceability, and speed directly affect trial execution, regulatory readiness, and patient impact. This role focuses on product strategy, user outcomes, workflow design, adoption, and measurable impact, in partnership with clinical, regulatory, safety, medical, data, technology, quality, vendor, and system owner teams.

Executive Director, Global Scientific Communications Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: As a new member of the Revolution Medicines team, the Executive Director, Global Scientific Communications will lead the development and execution of a comprehensive scientific communications strategy and team, ensuring alignment across internal and external stakeholders in preparation for the company's first commercial launch in pancreatic cancer and the progression of additional pipeline assets in NSCLC, colorectal cancer, and other solid tumors. Reporting into the SVP, Global Medical Affairs, this role will will be responsible for leading our scientific communications platforms and publication strategies and contribute to medical content supporting the organization's medical and scientific engagement efforts. Key responsibilities include: Publications Strategy & Execution - Lead the development and execution of the global publication plans, ensuring alignment with clinical and scientific objectives. - Oversee and provide strategic direction for medical writing, publication planning meetings, the submission process, and timely/high-quality scientific communications and

Associate Director, Regulatory Systems Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Associate Director, Regulatory Business Systems will lead the strategy, governance, implementation, and optimization of Regulatory Affairs technology platforms that support global regulatory operations and submission activities. This individual will serve as the business owner for key regulatory systems and partner closely with Regulatory Affairs, Regulatory Operations, IT, Quality, Clinical, and external vendors to deliver scalable, compliant, and efficient business solutions. The ideal candidate brings deep expertise in regulatory processes, business systems management, and cross-functional collaboration within a biotechnology or pharmaceutical environment. This role will play a critical part in advancing RevMed's regulatory systems roadmap and enabling operational excellence across the regulatory organization. Key Responsibilities: - Serve as the business owner and strategic lead for Regulatory Affairs systems, including Veeva RIM, Veeva Registrations, DocuBridge, and related regulatory platforms. - Drive the long-term strategy, roadmap, and governance model for regulatory business systems aligned with

Senior Manager, Commercial Regulatory Affairs Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Revolution Medicines is seeking a Senior Manager, Commercial Regulatory Affairs to partner closely with the cross-functional teams to ensure that all promotional and medical communication strategies are compliant with applicable regulations, industry standards, and internal policies. This role will help enable successful product commercialization while upholding regulatory integrity and scientific accuracy. As part of the Regulatory Affairs function, the Senior Manager will work under supervision to provide strategic regulatory advice on advertising/promotion and medical materials to the US organization for assigned products in accordance with business goals and objectives, FDA regulations/guidances, pharma guidelines, and company policy. The position can be based at our Redwood City, CA site in a hybrid work schedule (preferred) or remote-based with quarterly and as needed travel. Required Skills, Experience and Education: - Serves as a primary or secondary regulatory advertising and promotion reviewer for assigned products on

Senior Financial Analyst/Finance Manager Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Revolution Medicines is seeking a Sr. Financial Analyst/Finance Manager to support our growing needs in Development and R&D Finance. The successful candidate will have experience with clinical trials, R&D accruals process, month-end close, financial reporting, SOX, and audit support. This position is based out of our headquarters in Redwood City, CA. - Reporting to the Associate Director, FP&A and will serve as a business partner to Clinical Operations and cross-functional partner to Accounting, Finance, and Procurement. - Prepare month-end clinical trial accruals, including review of CRO reports, patient costs, and site payments. - Prepare monthly and quarterly reconciliations for accrued clinical and related prepaid accounts. - Contribute to Identify, design, and implement process improvements to streamline clinical trial accruals, reducing manual effort and improving accuracy and timeliness. - Review contracts and amendments to analyze and determine impact on clinical accruals. - Prepare contract

Director, Medical Analytics and Exploratory Data Science Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a highly motivated and scientifically rigorous Director of Biostatistics to our Medical Analytics and Exploratory Data Science Biostatistics group. This role will provide strategic and hands-on statistical leadership for exploratory data analyses, scientific publications, real-world evidence (RWE), post-marketing research, and health economics and outcomes research (HEOR) initiatives. The successful candidate will serve as a key statistical leader and individual contributor, partnering closely with cross-functional teams to generate high-quality evidence that advances our oncology pipeline and supports medical and scientific strategy. - Provide statistical leadership for exploratory data analyses using existing clinical trial data, real world data studies, post-marketing research, and HEOR projects. - Serve as a primary statistical contact for assigned projects, working collaboratively with clinical development, medical affairs, safety, statistical programming, regulatory affairs and commercial. - Lead the design, analysis, and interpretation of complex statistical models,

Director, Global Medical Affairs – GI Oncology Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Director, Global Medical Affairs will report to the GI Tumors Medical Affairs Strategy Lead and will be responsible for supporting the development and execution of the Global Medical Affairs (GMA) strategy and tactical plans for Revolution Medicines assets being developed for the treatment of GI cancers, with a focus on PDAC and CRC. Key aspects of this role include the following: support the development and execution of a Healthcare Professional (HCP) engagement strategy to gather insights that shape internal programs; act as the medical representative on cross-functional teams; serve as a therapeutic area content expert; and support medical affairs functions as needed. As a member of the GMA team, the successful candidate will participate in the Global Medical Affairs Team (GMAT) to execute medical strategies, contribute to the operations and oversight of medical activities, and work cross-functionally to support

Director, Global Patient Safety Operations Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a highly skilled and experienced Director of Global Patient Safety Operations to join our team. Reporting to the Head of Global Patient Safety Operations, this role provides leadership and oversight of safety operations, including management of pharmacovigilance vendors and serving as an internal subject matter expert. The Director will mentor and develop direct reports, execute the department's vision and strategy, and work collaboratively with cross-functional teams. In addition, the Director will collaborate cross-functionally to continuously develop and maintain the pharmacovigilance system to support Revolution Medicines' research, development, and marketed products. - Lead and manage direct reports of the Global Patient Safety Operations team - Oversee procedures related to Individual Case Safety Report processing, oversight of metrics, and compliance with global safety reporting requirements. - Oversee pharmacovigilance vendors and CROs, ensuring quality, budget, and timely delivery of safety operations activities.

Senior Director, Medical Affairs, Midsized Markets Europe Basel, Basel-Stadt, Switzerland Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Reporting to the VP, GM, Midsized Markets, the Senior Director, Medical Affairs, Midsize Markets Europe, is the medical leader responsible for defining and executing the medical strategy for oncology products in our portfolio within Midsized markets. This role serves as the medical voice within the Midsized markets Leadership Team, ensuring scientific excellence, compliant medical engagement, and strong alignment between global strategy and local patient, physician, and healthcare system needs. This leader will ensure that Midsized markets medical considerations are embedded in the regional medical strategy and plans and will partner with the Midsized markets country managers and crossfunctional teams, as well as VP Head of Europe Medical Affairs and their leadership team. The incumbent will contribute to building the Midsized markets medical team and working closely with the Global, Regional, Country Medical Affairs teams across Med Affairs functions. Responsibilities: - Act as

Senior Director, Clinical Development Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking an experienced clinical science drug developer to serve as Senior Director of Clinical Development in support of Revolution Medicines' clinical-stage molecule(s). In this critical role, you will support various clinical science deliverables and enable effective and efficient execution of the clinical development plan for a molecule(s) within its particular indication(s). The scope of activities spans early-stage clinical research to pivotal studies including regulatory submissions. You will play a vital role in leading the clinical science aspects of the Clinical Development Plan (CDP) strategy, driving the development of transformative therapies for patients. - Lead clinical science aspects of the clinical development strategy and clinical documentation. Represent the clinical development plan on appropriate teams, sub-teams and forums; oversee training of study site personnel, act as primary point-of-contact for questions/enquires regarding the CDP at a program level, oversee the conduct of medical/safety data

Vice President, Regulatory Affairs Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Vice President, Regulatory Affairs will manage several key U.S. based regulatory functions and report to the SVP of Regulatory and Quality. The position is responsible for expanding and leading a large, high functioning regulatory group and ensuring global alignment. - Provide ethical and mission-driven leadership of the Regulatory Affairs functions. Embody and practice the company's mission-driven culture. Ensure that our core values guide our strategic vision and our day-to-day decision making. - Provide a vision for the Regulatory Affairs organization and develop a plan to achieve it. Design and rapidly scale a group to meets the needs of an explosive pipeline in areas of high unmet medical need and intense industry competition. - Influence decision-making of senior leadership and ensure globally aligned regulatory decision-making. - Collaborate closely and form effective relationships with other functional heads and regional counterparts to ensure high quality,

Senior Manager, Compliance - Field Commercialization (East) Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Senior Manager, Compliance - Field Commercialization is responsible for providing hands-on support to Commercial and Medical field teams during product commercialization and indication expansion. This role serves as a primary field-facing compliance partner, ensuring compliant execution of field activities while enabling business objectives. Reporting to the Senior Director, Compliance the Senior Manager will implement and continuously enhance a comprehensive field-facing compliance program, embedding compliance into daily field operations while supporting the company's growth as commercial stage oncology organization. Field Compliance Support - This role will support the Senior Director, Compliance in providing field-facing corporate compliance support for all Revolution Medicines (RevMed) field roles, including field Sales, field Marketing, Medical Science Liaisons, and field Reimbursement and Access teams. - This role will serve as primary compliance contact for questions related to field activities. - The Senior Manager will partner with Headquarter Compliance,

Director, Biostatistics - Early Phase Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Playing a critical role as a lead statistician for clinical program(s) and studies and the subject matter expert (SME) in Biostatistics within Quantitative Sciences function, this position is to provide statistical leadership and support for clinical development strategy and clinical studies through product life cycle. - Provide statistical support and strategic input to clinical development plans and target product profiles, proof of concept criteria, and team's preparation for company governance reviews. - Represent Biostatistics function on cross-function teams at program level and serve as a lead statistician for oncology studies - Collaborate with various functions on study design and planning, protocol development, statistical analysis plan and analysis specifications. - Provide statistical support for study protocol development, analysis plan and specification through direct involvement and/or providing guidance to junior staff. - Plan and prepare independent data monitoring committee (DMC), coordinate with independent statistical

Vice President, Global CMC Regulatory Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking an accomplished, strategic and execution-oriented leaders, Vice President, Global CMC Regulatory, reporting to SVP of Pharmaceutical Development and Manufacturing (PDM) Regulatory, to lead our global chemistry, manufacturing, and controls (CMC) regulatory strategy and execution across all development programs and commercial assets. This leader will drive regulatory strategy development, lead regulatory interactions, and provide expertise throughout the product lifecycle, from early development to post-approval variations ensuring the timely submission and approval of high-quality CMC regulatory filings to support our company's pipeline and global growth. The successful candidate will serve as a senior leadership role within Pharmaceutical Development and Manufacturing (PDM) organization, overseeing CMC regulatory activities and ensuring alignment with health authority expectations globally (FDA, EMA, PMDA, NMPA, etc.). The role requires expertise in small molecule pharmaceutical development and manufacturing, an understanding of the oncology development lifecycle, and the ability to

Senior Clinical Program Manager Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: This is a unique opportunity for a Clinical Operations Professional. As a Sr. Clinical Program Manager, you will be responsible for acting as a central contact for the Clinical Study Team(s) and assist with the execution and management of Revolution Medicines (RevMed) clinical trials. Responsibilities: - Adhere to Clinical Standard Operating Procedures (SOP), Good Clinical Practice (GCP) and International Conference on Harmonization (ICH) Guidelines. - Be a team leader, providing guidance and oversight for the successful management of all aspects of clinical trials within timelines and designated program budgets. - Partner with cross-functional teams to manage, adjust, and revise project timelines and budgets as needed. - Analyze data health metrics to be shared with stakeholders. - Actively partner with cross-functional teams and vendors to drive the query resolution and data listings review process to meet objectives in a timely and efficient process. -

Vice President, Analytical Development & Quality Control Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a strategic and execution-driven Vice President, Analytical Development & Quality Control (ADQC) to lead the vision, strategy, and execution of analytical development and QC across our growing portfolio. Reporting to the Senior Vice President, Pharmaceutical Development & Manufacturing, this executive will build and scale a phase-appropriate, forward-looking analytical organization that enables rapid development of small molecule programs while positioning the company for late-stage development and global commercialization. As a key member of the PDM leadership team, this role will shape analytical strategy at the enterprise level, ensuring robust control strategies, regulatory readiness, and operational excellence across internal and external networks. Responsibilities: Strategic & Organizational Leadership - Define and drive the enterprise-wide analytical development and QC strategy aligned with portfolio and corporate objectives. - Build, lead, and scale a high-performing ADQC organization to support a multi-asset oncology pipeline.